Healthcare updates 06/05/2026
Top items
Eli Lilly began enforcing its 340B claims-data policy on June 1 and will instruct wholesalers to cut off 340B pricing on June 8 for noncompliant covered entities — the holdouts are explicitly the large DSH hospitals, i.e. your exact profile, and the affected drugs include tirzepatide. An "initial set" of holdouts were notified that Lilly's wholesalers will pull their 340B pricing eligibility on June 8 if they do not submit the outstanding data, with the same to follow for remaining noncompliant entities in the weeks ahead.
Indiana's elimination of 340B reimbursement under Medicaid managed care is still set for July 1 — and the FQHC carve-out the Governor granted in April does NOT extend to hospitals. The exemption does not apply to Indiana hospitals, which raised similar concerns about the elimination of 340B reimbursement for Medicaid.
The Section 232 onshoring-agreement application deadline is June 12 (next Friday); patented Part B infusion and specialty lines remain exposed to the tariff tiers, while retail and biosimilars stay carved out.
UnitedHealthcare is expanding its commercial site-of-care program to select oncology infusibles effective August 1 — direct pressure on hospital outpatient infusion margins. Effective August 1, 2026, the site of care program is being expanded to include select oncology medications for UnitedHealthcare commercial business.
The full Fourth Circuit agreed (May 28) to rehear the West Virginia and Maryland contract-pharmacy cases en banc, vacating the manufacturer-friendly panel rulings — a national signal, though Indiana sits in the Seventh Circuit. The 4th U.S. Circuit Court of Appeals May 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland; in April, a three-judge panel found those laws unconstitutional.
Drug Channels' new contract-pharmacy analysis (June 3) confirms five vertically integrated giants now control 77% of all 340B contract-pharmacy relationships — relevant as you negotiate specialty and contract-pharmacy arrangements. In 2026, five publicly traded mega-corporations—Cigna, CVS Health, UnitedHealth Group, Walgreens, and Walmart—are capturing 77% of all 340B contract pharmacy relationships.
Section 1 - Federal Regulatory
FDA.
A quiet-but-relevant week for some service lines. The agency issued draft guidance on June 2 to accelerate cell and gene therapy development, and on May 29 issued draft guidance to reduce animal testing for cancer drugs. FDA issued draft guidance June 2 to help accelerate cell and gene therapies, and on May 29 issued draft guidance to cut unnecessary animal testing for cancer drugs.
On approvals, FDA approved Xocova (ensitrelvir), the first oral option for post-exposure prevention of COVID-19, announced June 1 (approval dated May 29), and approved Zaynich (cefepime/zidebactam) for complicated UTIs on May 30. Read-through for a cancer/immunology/infusion system.
The CGT guidance is worth a tab-keep given those products are also Section 232–exempt (see 1B), but it changes no acquisition or formulary decision this week.
CMS.
The material movement is on the GLP-1 Bridge, which CMS updated its provider and beneficiary pages for on June 2–3. The drug list is now firm: beginning July 1, 2026, all formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound will be available; the single-dose vial and single-dose pen formulations of Zepbound will not be. CMS said it will provide additional information on the prior-authorization process in June 2026, including the Medicare GLP-1 Bridge PA form. As background context that did change recently: the longer-term BALANCE model was shelved, and the Bridge was stretched from 6 to 18 months. The Bridge now runs 18 months rather than the originally intended six and remains a demonstration with no statutory backing; BALANCE was shelved indefinitely by CMS in April 2026. Economics unchanged from prior brief: manufacturers provide eligible GLP-1s at a net price of $245 per month; pharmacies collect a $50 copay and are reimbursed by CMS at no lower than WAC less the copay, plus a dispensing fee.
Three scenarios here for those interested in implemenatation
Scenario A — Full stacking. Acquire at 340B ceiling, reimbursed at WAC, manufacturer still owes CMS the rebate. Captures the full WAC–340B spread. This is the post's implied windfall. Least likely to be permitted or durable — it's the configuration manufacturers and CMS have every incentive to foreclose.
Scenario C — Offset / lesser-of. Some netting mechanism prevents double-dipping (e.g., 340B available but reimbursement or rebate adjusted). Intermediate margin. Plausible if CMS mirrors the IRA approach.
Scenario B — Carve-out / no 340B on Bridge units. Acquire outside 340B; margin ≈ dispensing fee. Most likely base case and the safe default.
DEA (Diversion Control).
Nothing material this period. The live item remains the permanent telemedicine controlled-substance rule (special registration), still pending; the current COVID-era flexibilities are extended through December 31, 2026. No change this period; next trigger is the permanent rule's release from OMB.
HRSA (Office of Pharmacy Affairs)
No litigation or rulemaking movement this week. For continuity: the original 340B Rebate Model Pilot is effectively dead after the Maine court enjoined it in December and the First Circuit declined a stay, HHS told the courts in February it would pull the relevant notices and application approvals, filing a joint motion for vacatur and remand. The live thread is HRSA's successor RFI which AHA continues to oppose outright. No change this period; watch for whether HRSA re-proposes a rebate model with a cleaner APA record.
Courts.
The headline is the Fourth Circuit en banc grant (above). For your jurisdiction specifically, this does not bind Indiana — but it matters because it reopens the only appellate losses manufacturers had secured on contract-pharmacy access laws, against a backdrop where the Fifth and Eighth Circuits have upheld similar laws in Louisiana and Arkansas. The circuit split is widening, which raises the odds of eventual Supreme Court review of the contract-pharmacy question.
Section 1B — Trade & Tariff Policy (Pharmaceutical)
This is the section carrying the most directly actionable manufacturer- and formulary-specific signal.
(1) BIS notices and the onshoring-agreement window — the live action item. The single date that matters this week is June 12, now seven days out. BIS's Federal Register notice (published May 13) requests onshoring-agreement applications by June 12, 2026, submitted to pharma232@bis.doc.gov. The benefit ladder is unchanged: companies not in Annex III face a 100% tariff effective September 29, 2026; an approved onshoring agreement reduces the duty to 20%, and an onshoring agreement plus an MFN pricing agreement reduces it to 0% until January 20, 2029. The most recent confirmed manufacturer MFN deal remains Regeneron (the 17th), back on April 23. The Regeneron agreement, reached April 23, was the 17th most-favored-nation drug pricing agreement with the administration. Expect a cluster of announcements as the deadline lands.
Read-through: any manufacturer whose patented infusibles you buy that signs by June 12 moves toward a 20%/0% rate; the acquisition-cost relief flows to you only indirectly, through avoided WAC increases, not through a tariff line you pay directly.
(2) Generic / biosimilar extension signal. No movement toward extension this week. The statutory clock is unchanged: within one year of the proclamation, the Secretary must advise the President of any circumstances indicating a need to extend Section 232 tariffs to generic pharmaceuticals and their ingredients. That advisory is due by April 2, 2027. No change this period.
(3) MFN ↔ CMMI-model interaction. No new MFN agreement and no new CMS clarification this week on how MFN deals interact with GLOBE/GUARD/Bridge. The unresolved confusion persists: manufacturers with MFN agreements have claimed exemption from GLOBE and GUARD, and Congress has formally asked HHS to clarify which drugs remain subject to those models. No change this period; the clarification is still owed. For the GLP-1 thread specifically, the Bridge's $245 net price is a negotiated demonstration price, distinct from the tariff tiers — so the Bridge does not change your GLP-1 tariff exposure.
(4) Adjacent Section 232 tracks (devices, consumables, PPE, robotics). No determination this week. As background, Commerce opened Section 232 investigations on September 26, 2025 into (1) PPE and medical consumables, equipment, and devices and (2) robotics and industrial machinery. These remain open with no public finding. No change this period. If/when a device-and-consumables finding lands, the supply-chain hit is broader than drugs — infusion pumps, sets, and disposables — so it is worth a standing tripwire even though it is not pharmacy-coded.
(5) Litigation. No suit specifically challenging the Section 232 pharmaceutical tariffs has surfaced. The important legal read-through is that the February 20 Supreme Court ruling striking down the IEEPA tariffs does not help anyone hoping the pharma tariffs fall — it cuts the other way. The Court's ruling applies only to tariffs imposed under IEEPA and does not apply to tariffs imposed under Section 232 of the Trade Expansion Act of 1962. In the opinion itself, Chief Justice Roberts pointed to Section 232 as an example of Congress delegating tariff power "in explicit terms, and subject to strict limits." Translation: the pharmaceutical tariff regime sits on firmer legal ground after February, not weaker.
Section 2 — Payer Policy Updates
UnitedHealthcare — material. UHC is expanding its commercial site-of-care steerage to oncology. Effective August 1, 2026, UnitedHealthcare is expanding its site of care program to include select oncology medications under commercial business. This was published in UHC's May specialty-medical-injectable update, so it is recently announced rather than strictly this week, but the August 1 effective date puts it in actionable range. Site-of-care programs push provider-administered drugs out of hospital outpatient departments toward home infusion, freestanding centers, or physician offices — the alternate site of care will be a participating infusion provider (home infusions), physician office, or freestanding infusion center. For a 340B DSH system, oncology infusion moving out of the HOPD is both a margin hit and a 340B-capture hit. This pairs with UHC's ongoing white-bagging ("medication sourcing") regime requiring outpatient hospitals to obtain certain specialty drugs from designated specialty pharmacies.
Section 3 — Industry Intelligence
The Lilly 340B enforcement action (also the lead item) — operational detail. This is the highest-signal industry story of the week and it is operational, not theoretical. Enforcement starts with June 1 notices giving select covered entities five business days to submit required claims data or lose access to 340B pricing; the expanded January 2026 policy adds in-house pharmacy dispenses to existing contract-pharmacy reporting, requiring 14 medical-claim fields and 18 in-house pharmacy fields. Lilly's framing: it reports roughly 70% compliance (about 2,350 entities) and nearly 800,000 in-house claims received, characterizing resistance as a coordinated DSH-led boycott. Scale of the holdouts: Lilly maintains nearly 1,000 hospitals have refused to submit requested claims data. The mechanism is what makes this novel and copyable — Lilly is not suing; it is instructing wholesalers to stop extending 340B pricing, which is faster and harder to enjoin. AHA and 340B Health are pressing HHS/HRSA to intervene and have called the policy unlawful. The cross-cutting fact for you: at least six other drug companies have announced data policies requiring 340B hospitals to provide pharmacy and medical claims data. If Lilly's wholesaler-cutoff works on June 8, expect the others to adopt the same playbook.
Manufacturer contract-pharmacy restrictions. Continued tightening this period: LEO Pharma announced May 27 that new contract-pharmacy restrictions on an injectable atopic-dermatitis medication take effect June 22, and AstraZeneca has become the latest manufacturer to announce 340B in-house pharmacy data requirements. The atopic-dermatitis restriction is immunology-line-relevant.
Drug Channels — high-signal analysis (June 3). Adam Fein's latest exclusive on the 340B contract-pharmacy market is the analytical piece : five publicly traded mega-corporations—Cigna, CVS Health, UnitedHealth Group, Walgreens, and Walmart—are capturing 77% of all 340B contract-pharmacy relationships in 2026.
Specialty pharmacy / PBM consolidation. The relevant standing context: successive stays since early 2026 have delayed the FTC's antitrust proceedings against Optum Rx, pointing to a potential consent agreement in the works, after Express Scripts settled the insulin case in February.
AI / pharmacy automation. The most recent concrete item is Surescripts, not this week but recent: Surescripts expanded its Prior Authorization Automation, now available to 68,000 prescribers across 42 health systems with another 119,000 expected to go live in 2026, citing an 18-second median approval time when criteria are met.
Drug shortages. Nothing new with material oncology/infusion clinical impact surfaced this week. The chronic vulnerability (sterile injectables and oncology generics) is unchanged.
Section 4 — Closing: Three Things to Watch
1. Regulatory deadlines and court dates in the next 30 days. This is an unusually dense month. June 8 — Lilly's wholesaler cutoff for the initial noncompliant cohort. June 12 — Section 232 onshoring-agreement application deadline (and, coincidentally, Drug Channels' 340B market webinar the same day). July 1 — Indiana's Medicaid 340B reimbursement cutoff for hospitals and the GLP-1 Bridge go-live, the same day. Then the standing Section 232 tripwires carried forward: July 31 (Annex III tariffs effective for the 17 large manufacturers) and September 29 (all-other effective). The June 12 onshoring deadline now sits before the July 31 Annex III date — so the next two weeks set the tier structure that determines the July 31 invoice reality.
2. Manufacturer or payer moves that may break in the coming week. Whether Lilly actually executes the June 8 cutoff — and whether HRSA intervenes before it does — is the binary event. If Lilly proceeds and HRSA stays silent, expect at least one of the six other manufacturers with data policies to announce its own enforcement timeline within days. Separately, watch for a burst of onshoring/MFN signings as June 12 approaches; any manufacturer of a patented infusible on your formulary that signs is a near-term WAC-stability signal.
3. Not-yet-news, but structurally likely. Two. First, the enforcement-by-wholesaler model Lilly is piloting is the real innovation here — it sidesteps the litigation that has tied up other manufacturer restrictions. Once it's shown to work operationally, it becomes the template, and the 340B data fight shifts from "will hospitals report" to "can wholesalers be compelled not to cut off." Second, and longer-fuse: the generic/biosimilar Section 232 carve-out is protected only until the April 2, 2027 advisory. As that date approaches, expect Commerce signaling on whether to extend tariffs to generics and biosimilars — and that is the development that would breach your currently-safe retail and biosimilar lines. There is no public signal toward it yet, which is precisely why it belongs here rather than above.
